UPDATE: OPKO Health (OPK) Easily Tops Q3 Views
(correction: EPS corrected)
OPKO Health (NYSE: OPK) reported Q3 EPS of %0.25, 27 cents better than the analyst estimate of ($0.02). Revenue for the quarter came in at $143 million versus the consensus estimate of $132.99 million.
OPKO has already achieved numerous important milestones during 2015,” said Phillip Frost, M.D., Chairman and CEO. “We believe that the Pfizer transaction for hGH-CTP and the acquisitions of EirGen and Bio-Reference Laboratories have had a positive impact on our financial operations and will provide significant revenue opportunities and an expanded commercial platform for us going forward. The addition of our 4Kscore® Test to the NCCN guidelines was an important step toward obtaining reimbursement from healthcare payors, a key factor for obtaining broad access to men for the test. Our NDA filing for Rayaldee™ continues to advance through the FDA drug approval process and we have high expectations for our new treatment option for patients with stage 3 or 4 chronic kidney disease and secondary hyperparathyroidism. Our clinical development programs for Factor VIIa-CTP and oxyntomodulin, each with great commercial potential, are advancing on plan and we expect to initiate human trials for both products in the near future,” continued Dr. Frost.
For earnings history and earnings-related data on OPKO Health (OPK) click here.